Non-Gaussian Features of Transmitted Flux of QSO's Lyα\alpha Absorption: Intermittent Exponent

We calculate the structure function and intermittent exponent of the 1.) Keck data, which consists of 29 high resolution, high signal to noise ratio (S/N) QSO Ly$\alpha$ absorption spectra, and 2.)the Ly$\alpha$ forest simulation samples produced via the pseudo hydro scheme for the low density cold dark matter (LCDM) model and warm dark matter (WDM) model with particle mass $m_W=300, 600, 800$ and 1000 eV. These two measures detect not only non-gaussianities, but also the type of non-gaussianty in the the field. We find that, 1.) the structure functions of the simulation samples are significantly larger than that of Keck data on scales less than about 100 h$^{-1}$ kpc, 2.) the intermittent exponent of the simulation samples is more negative than that of Keck data on all redshifts considered, 3.) the order-dependence of the structure functions of simulation samples are closer to the intermittency of hierarchical clustering on all scales, while the Keck data are closer to a lognormal field on small scales. These differences are independent of noise and show that the intermittent evolution modeled by the pseudo-hydro simulation is substantially different from observations, even though they are in good agreement in terms of second and lower order statistics. (Abridged)Comment: 17 pages, 13 figures. Accepted by Ap

Response to the letter by Udo Bonnet

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/153273/1/nmo13715_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/153273/2/nmo13715.pd

Band Gap Engineering with Ultralarge Biaxial Strains in Suspended Monolayer MoS2

We demonstrate the continuous and reversible tuning of the optical band gap of suspended monolayer MoS2 membranes by as much as 500 meV by applying very large biaxial strains. By using chemical vapor deposition (CVD) to grow crystals that are highly impermeable to gas, we are able to apply a pressure difference across suspended membranes to induce biaxial strains. We observe the effect of strain on the energy and intensity of the peaks in the photoluminescence (PL) spectrum, and find a linear tuning rate of the optical band gap of 99 meV/%. This method is then used to study the PL spectra of bilayer and trilayer devices under strain, and to find the shift rates and Gr\"uneisen parameters of two Raman modes in monolayer MoS2. Finally, we use this result to show that we can apply biaxial strains as large as 5.6% across micron sized areas, and report evidence for the strain tuning of higher level optical transitions.Comment: Nano Lett., Article ASA

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and molecular heterogeneity. We used integrative molecular profiling to discover and characterize molecular subtypes of LMS. Gene expression profiling was performed on 51 LMS samples. Unsupervised clustering showed three reproducible LMS clusters. Array comparative genomic hybridization (aCGH) was performed on 20 LMS samples and showed that the molecular subtypes defined by gene expression showed distinct genomic changes. Tumors from the muscle-enriched cluster showed significantly increased copy number changes (P=0.04). A majority of the muscle-enriched cases showed loss at 16q24, which contains Fanconi anemia, complementation group A, known to have an important role in DNA repair, and loss at 1p36, which contains PRDM16, of which loss promotes muscle differentiation. Immunohistochemistry (IHC) was performed on LMS tissue microarrays (n=377) for five markers with high levels of messenger RNA in the muscle-enriched cluster (ACTG2, CASQ2, SLMAP, CFL2 and MYLK) and showed significantly correlated expression of the five proteins (all pairwise P<0.005). Expression of the five markers was associated with improved disease-specific survival in a multivariate Cox regression analysis (P<0.04). In this analysis that combined gene expression profiling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers

Trisomy Correction in Down Syndrome Induced Pluripotent Stem Cells

SummaryHuman trisomies can alter cellular phenotypes and produce congenital abnormalities such as Down syndrome (DS). Here we have generated induced pluripotent stem cells (iPSCs) from DS fibroblasts and introduced a TKNEO transgene into one copy of chromosome 21 by gene targeting. When selecting against TKNEO, spontaneous chromosome loss was the most common cause for survival, with a frequency of ∼10−4, while point mutations, epigenetic silencing, and TKNEO deletions occurred at lower frequencies in this unbiased comparison of inactivating mutations. Mitotic recombination events resulting in extended loss of heterozygosity were not observed in DS iPSCs. The derived, disomic cells proliferated faster and produced more endothelia in vivo than their otherwise isogenic trisomic counterparts, but in vitro hematopoietic differentiation was not consistently altered. Our study describes a targeted removal of a human trisomy, which could prove useful in both clinical and research applications

Liquid-like thermal conduction in a crystalline solid

A solid conducts heat through both transverse and longitudinal acoustic phonons, but a liquid employs only longitudinal vibrations. Here, we report that the crystalline solid AgCrSe2 has liquid-like thermal conduction. In this compound, Ag atoms exhibit a dynamic duality that they are exclusively involved in intense low-lying transverse acoustic phonons while they also undergo local fluctuations inherent in an order-to-disorder transition occurring at 450 K. As a consequence of this extreme disorder-phonon coupling, transverse acoustic phonons become damped as approaching the transition temperature, above which they are not defined anymore because their lifetime is shorter than the relaxation time of local fluctuations. Nevertheless, the damped longitudinal acoustic phonon survives for thermal transport. This microscopic insight might reshape the fundamental idea on thermal transport properties of matter and facilitates the optimization of thermoelectrics.Comment: four figures, supplemental informatio

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Disease-modifying therapies; Multiple sclerosis; OcrelizumabTerapias modificadoras de la enfermedad; Esclerosis múltiple; OcrelizumabTeràpies modificadores de la malaltia; Esclerosi múltiple; OcrelizumabOpen-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase 2 trial on the longest follow-up to date of ocrelizumab-treated patients with relapsing–remitting MS (RRMS). The primary treatment period (PTP) comprised four 24-week treatment cycles; participants were randomized to double-blind ocrelizumab (2000 mg or 600 mg), placebo, or interferon β-1a (open label) for one cycle, then dose-blinded ocrelizumab 1000 mg or 600 mg for the remaining cycles. The PTP was followed by consecutive assessed and unassessed treatment-free periods (TFPs) and then the OLE (ocrelizumab 600 mg every 24 weeks). Safety and efficacy were prospectively assessed. Of 220 participants randomized, 183 (84%) completed the PTP. After the TFP, 103 entered OLE (median OLE ocrelizumab exposure 6.5 years). Most common adverse events across all periods were infusion-related reactions. MRI activity, annualized relapse rate, and confirmed disability progression (CDP) rates remained low throughout. During the assessed TFP, there was a trend toward less and later B-cell repletion, and later CDP, for patients randomized to ocrelizumab; MRI activity was observed in 16.3% of patients, the earliest 24 weeks after the last ocrelizumab dose. This is the longest follow-up of ocrelizumab-treated patients with RRMS, with no new safety signals emerging during an observation period from 2008 to 2020. Results reinforce the sustained efficacy of long-term ocrelizumab. Reduced disease activity was maintained following interruption of 6-month dosing cycles, with no evidence of rebound.This research was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Editorial assistance for this article was provided by Nicholas Fitch and Martha Hoque of Articulate Science, UK, and funded by F. Hoffmann-La Roche Ltd. The authors had full editorial control of the manuscript and provided their final approval of all content